Combination of cyclophosphamide and interferon-β halts progression in patients with rapidly transitional multiple sclerosis

Journal of Neurology Neurosurgery and Psychiatry

Volumn 71, Issue 3, 2001, Pages 404-407

  Patti, F ^a   Cataldi, M L ^a   Nicoletti, F ^b   Reggio, E ^a   Nicoletti, A ^a   Reggio, A ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Cyclophosphamide; Interferon ; Multiple sclerosis

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DOSE RESPONSE; FEMALE; HUMAN; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE SCLEROSIS; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TREATMENT FAILURE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGE OF ONSET; ANALYSIS OF VARIANCE; CD4-CD8 RATIO; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISABLED PERSONS; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; LYMPHOCYTE COUNT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; NEUROLOGIC EXAMINATION; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 0034880661     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.71.3.404     Document Type: Article

References (21)

1. Weinstock-Guttman B, Kinkel RP, Cohen JA, et al. Treatment of "transitional MS" with cyclophosphamide and methyl-prednisolone (CTX-MP) followed by interferon-β [abstract]. Neurology 1997;48(suppl 2):A341.
2. Goodkin DE. Interferon beta therapy for multiple sclerosis. Lancet 1998;352:1486-7.
3. The Canadian cooperative trial of cyclophosphamide and plasma-exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group. Lancet 1991;337:441-6.
4. Weiner HL, Dau PC, Khatri B, et al. Doulble-blind study of true v sham plasma-exchange in patients treated with immunosuppression for acute attacks of multiple sclerosis. Neurology 1989;39:1143-9.
5. Gonsette RE. Introductory remarks: immunosoppressive and immunomodulating drugs, where and how do they act? Mult Scler 1996;1:306-12.
6. Ormerod IE, Miller DH, McDonald WI, et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 1987;110:1579-616.
7. Myers LW, Fahey JL, Moody DJ, et al. Cyclophosphamide "pulse" in chronic progressive multiple sclerosis. Arch Neurol 1987;44:828-32.
8. McAlpine D. Course and prognosis of multiple sclerosis. In: McAlpin D, Compston ND, Lumsden CE, eds. Multiple sclerosis. Edinburgh: Livingstone, 1955:135-55.
9. Uitdehaag BMJ, Nillesen WM, Hommes OR. Long-lasting effects of cyclophosphamide on lymphocytes in peripheral blood and spinal fluid. Acta Neurol Scand 1989;79:12-17.
10. Comabella M, Balashov K, Issazadeh S, et al. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest 1998;102:671-8.
11. Takashima H, Smith DR, Fukara H, et al. Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen specific IL-4 secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol 1998;88:28-34.
12. Bryniarski K, Ptak M, Ptak W. The in vivo and in vitro effects of an alkylating agent, mechlorethamine, on IL-6 production in mice and a role of macrophages. Immunopharmacology 1996;34:73-8.
13. Moody DJ, Fahey JL, Grable E, et al. Administration of monthly pulses of cyclophosphamide in multiple sclerosis patients. Delayed recovery of several immune parameters following discontinuation of long-term cyclophosphamide treatment. J Neuroimmunol 1987;14:175-82.
14. Hommes OR, Prick JJ, Lamers KJ. Treatment of the chronic progressive form of multiple sclerosis with a combination of cyclophosphamide and prednisone. Clin Neurol Neurosurg 1975;78:59-72.
15. Gobbini MI, Smith ME, Richert ND, et al. Effect on open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. J Neuroimmun 1999;99:142-9.
16. Weiner HL, Mackin GA, Orav EJ, et al. Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology 1993;43: 910-18.
17. Hohol Mj, Olek MJ, Orav EJ, et al. Treatment of progressive multiple sclerosis with pulse cyclophosphamide/ methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler 1999;5:403-9.
18. Goodkin DE, Plencner S, Palmer-Saxerud J, et al. Cyclophosphamide in chronic progressive multiple sclerosis. Manteinance v non-manteinance therapy. Arch Neurol 1987;44:823-7.
19. Trapp BD, Peterson J, Ransohoflf RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998; 338:278-85.
20. Storch M, Lassmann H. Pathology and pathogenesis of demyelinating diseases. Curr Opin Neurology 1997;10:186-92.
21. Weber F, Polak T, Gunther A, et al. Synergistic immunomodulatory effects of interferon-β 1b and phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol 1998;44:27-34.